CHICAGO, August 12, 2015 /PRNewswire/ --
Providing a snapshot of the global therapeutic spinal cord injury pipeline and landscape along with a summary of all the dormant and discontinued pipeline projects, the Spinal Cord Injury - Pipeline Review market research report focuses primarily on H1 2015 period.
Complete report on spinal cord injury market pipeline spread across 225 pages, talking about 36 major companies and institutes as well as supported with 63 tables and 15 figures is now available at http://www.rnrmarketresearch.com/spinal-cord-injury-pipeline-review-h1-2015-market-report.html .
The ‘Spinal Cord Injury - Pipeline Review, H1 2015 market research report provides comprehensive information on the therapeutic development for spinal cord injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects.
The report summarizes all the dormant and discontinued spinal cord injury pipeline projects. A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is provided along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are also covered.
Companies mentioned in this spinal cord injury market pipeline report include Acorda Therapeutics, Inc., Asubio Pharma Co., Ltd., Athersys, Inc., Axerion Therapeutics, Inc., BioArctic Neuroscience AB, Faron Pharmaceuticals Oy, FirstString Research, Inc., Genervon Biopharmaceuticals, LLC, Grupo Ferrer Internacional, S.A., Hemostemix Ltd, Histocell S.L., Intellipharmaceutics International Inc., K-Stemcell Co., Ltd., Kadimastem Ltd., Kringle Pharma, Inc., Lipopharma Therapeutics SL, Lpath, Inc., MandalMed, Inc., Mapreg S.A.S., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neuronax SAS, Omeros Corporation, PharmatrophiX, Inc., Pharmicell Co., Ltd., Q Therapeutics, Inc., Quark Pharmaceuticals, Inc.,
Remedy Pharmaceuticals, Inc., RhinoCyte, Inc., SanBio, Inc., Sirnaomics, Inc., StemCells, Inc., Stemedica Cell Technologies, Inc., TissueGene, Inc., Vertex Pharmaceuticals Incorporated and Vicore Pharma AB. Drug profiles mentioned in this research cover (buspirone + levodopa + carbidopa), ACTX-08, Antibody to Inhibit RGM for Spinal Cord Injury, AP-325, AST-OPC-1, Astrostem, AX-007, BA-277, BA-434, C-21, Cell Therapy for Spinal Cord Injury, Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury,
Cerecellgram-Spine, CHEC-7, CHEC-9, chondroitinase ABC nanosphere, cimaglermin alfa, CLR-01, CM-101, Drug for Spinal Cord Injury, Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury, FIB-117, glyburide, GM-603, HBN-1, HC-016, HuCNS-SC, ICCN-100, IMS-001, IMS-002, interferon beta-1a, KP-100IT, LM11A-31, LPA-181, Lpathomab, MAP-4343, MultiStem, NCP-01, Neural Stem Cells, neurovitas, NgR(310)ecto-Fc, NRP-2945, NSI-566, NX-210, Oligonucleotide for Central Nervous System and Metabolic Disorders, Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury, Peptides for Central Nervous System and Musculoskeletal Disorders, pregabalin ER, PT-00114, Q-Cells, Recombinant Protein for Spinal Cord Injury, SB-618, SB-623, SC-0806, siRNA for CNS Disorders, Small Molecule to Antagonize GPR17 for Central Nervous System Disorders, Small Molecules for Spinal Cord Injury, Stem Cell Therapy for Acute Spinal Cord Injury, Stem Cell Therapy for CNS Disorders, Stem Cell Therapy for Neurodegenerative Disorders, Stem Cell Therapy for Spinal Cord Injury, STP-805, SUN-13837, Synthetic Peptide for Spinal Cord Injuries, Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease, Tenascin-C Fragments for Spinal Cord Injury, TG-N, UH-0113, UH-0213 and VX-210. Order a copy of Spinal Cord Injury - Pipeline Review, H1 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=400822 .
Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from a proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
On pipeline reviews and clinical trials, RnRMarketResearch.com offers a range of newly published as well as relevant research titles:
Acute Spinal Cord Injury - Pipeline Review, H1 2015: Along with concerned drug profiles, companies like Acorda Therapeutics, Inc, Kringle Pharma, Inc., Neuralstem, Inc. and Neuronax SAS are mentioned in this 52 pages report available at http://www.rnrmarketresearch.com/acute-spinal-cord-injury-pipeline-review-h1-2015-market-report.html .
Brain Injury Global Clinical Trials Review, H1, 2015: This report provides top line data relating to the clinical trials on Brain Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Clinical trial overview of companies like Pfizer Inc., ZonMw, Novo A/S, Cato Research Ltd., Canbex Therapeutics Ltd., AstraZeneca PLC, Astellas Pharma Inc., AmKor Pharma, Inc., Actavis Plc and of universities and government institutes like Vanderbilt University, ALYN Pediatric and Adolescent Rehabilitation Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Shaanxi Provincial People's Hospital, Tabriz University of Medical Sciences, University of Nottingham, Assistance Publique - Hopitaux de Paris, Associacao de Assistencia a Crianca Deficiente, Atlantic Health System and Baycrest are mentioned in this research spread across 87 pages and available at http://www.rnrmarketresearch.com/brain-injury-global-clinical-trials-review-h1-2015-market-report.html .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
1 South Dearborn Street,
21st Floor, Chicago,
SOURCE RnR Market Research